On May 29, 2025 Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, reported that it will present new clinical data at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago, IL (Press release, Diakonos Oncology, MAY 29, 2025, View Source [SID1234653495]). The presentation, titled "Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results," will highlight findings from the company’s Phase I trial of Dubodencel (DOC1021), a double-loaded dendritic cell therapy being evaluated for the treatment of glioblastoma, a highly aggressive brain tumor with a median overall survival of 14-18 months despite standard care. The study, recently completed, offers hope for improving outcomes in this devastating disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We will present the latest results in the evaluation of Dubodencel’s potential to enhance immune responses against glioblastoma, even in patients with poor prognostic factors," said Jay Hartenbach, President and COO of Diakonos Oncology. "Our approach focuses on leveraging the immune stimulating potential of dendritic cells, which play a crucial role in the adaptive immune response and can be exploited to provoke an intense and specific response to a patient’s tumor."

Presentation Details
Title: Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results
Authors: Joseph Georges, Christina Clay, Sabina Amin, Joseph Ifrach, Briana Burns, Akshar Trivedi, Wei Liu, Madhuri Namekar, Keenan Ernste, Vinod Ravi, Sigmund Hsu, Jay-Jiguang Zhu, Rodrick Zvavanjanja, Yoshua Esquenazi, Nitin Tandon, Alan Turtz, Laura Aguilar, Vanaja Konduri, William Decker
Abstract Number: 2014
Session Type: Rapid Oral Abstract Session
Session Title: Central Nervous System Tumors
Track: Central Nervous System Tumors
Sub Track: Primary CNS Tumors–Glioma
Session Date and Time: May 31, 2025, 3:00 PM-4:30 PM CDT
Location: Room S102, McCormick Place

About Dubodencel

Dubodencel, also known as DOC1021, is a first-in-class, double-loaded autologous dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient’s dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.

The unique double loading approach, which mimics a viral infection, unlocks a synergistic and exponentially more powerful tumor killing TH1 response driven by dual protein and RNA antigen sourcing, and it allows targeting of the complete cancer antigen pool. Moreover, the approach does not require any molecular modification of the patient’s immune cells for manufacturing, and does not require preconditioning of bone marrow or high dose IL-2 for administration. Dubodencel allows for a simple administration in the outpatient setting and broad reach via community cancer centers.

In addition to the recently opened Phase 2 GBM study, a clinical trial of Diakonos’ dubodencel is ongoing for the treatment of pancreatic cancer. Diakonos has received Fast Track designations from the FDA for both the GBM and pancreatic cancer programs, in October 2023 and May 2024, respectively. The company has also received Orphan Drug Designation for the GBM program in January 2024.

On May 29, 2025 Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies reported that three abstracts featuring new clinical data from tumor-infiltrating lymphocytes (TIL) therapies will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 42nd annual meeting, which is taking place in Chicago, IL from May 30th to June 3rd (Press release, Grit Bio, MAY 29, 2025, View Source [SID1234653494]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Grit Bio will provide the clinical updates of its leading TIL programs, including GT101 – an unmodified TIL therapy in treating recurrent and metastatic cervical cancer, GT201 – an armored TIL product expressing membrane bond IL-15 complex in treating various solid tumors, and GT300 – a CRISPR/Cas-edited dual KO TIL product in treating advanced solid tumors. The details of Grit Bio’s poster presentations are included below. The abstracts were published via the ASCO (Free ASCO Whitepaper) website on May 22, 2025.

Title: GT101 autologous TIL therapy in patients with recurrent and metastatic cervical cancer: A phase 1 study.
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Sunday, June 1st
Poster # 431
Abstract #: 5533
Title: Assessing the Safety and Efficacy of GT201: A First-in-Class Autologous Tumor-Infiltrating Lymphocyte Monotherapy in Advanced Solid Tumors
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Monday, June 2nd
Poster #: 446
Abstract #: 6038
Title: Evaluating the Safety and Efficacy of CRISPR/Cas-Modified Tumor Infiltrating Lymphocytes (GT300) as Monotherapy in Advanced Solid Tumors
Presentation Type: Poster
Time: 9:00 AM-12:00 PM CT, Sunday, June 1st
Poster #: 511
Abstract #: 5613
"We have harnessed cutting-edge technologies, including advanced gene editing tools, to enhance the potency and persistence of our TIL products, enabling the development of multiple differentiated TIL pipelines." said Dr. Yarong Liu, Founder and Chief Executive Officer of Grit Biotechnology. "These therapies have demonstrated promising clinical potential across a wide range of indications. Looking forward, we remain committed to accelerating their clinical advancement and actively seeking global collaborations to bring these transformative therapies to patients worldwide."

On May 29, 2025 Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University—and Hackensack University Medical Center reported research findings from 32 studies at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, John Theurer Cancer Center, MAY 29, 2025, View Source [SID1234653493]). The meeting is the premier event for cancer professionals and takes place in Chicago from May 30 to June 3.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The future of cancer treatment begins with the pioneering exploration being carried out today," notes Andre Goy, MD, chair, vice president, physician-in-chief of oncology, at Hackensack Meridian John Theurer Cancer Center. "We are fortunate to be in a time where many cancers will respond to standard treatments. But for those cancers that don’t, it’s critical that patients have access to a world-class research program that will yield innovative therapies. At John Theurer Cancer Center, our globally recognized investigators continue to drive the latest oncology advances in cellular therapy, immunotherapy and other areas, enabling improved outcomes for patients across the Hackensack Meridian Health network and beyond."

Several studies address novel drug combinations for multiple myeloma, as well as racial disparities in treatment outcomes and the expression of key biomarkers. Investigators are also presenting data on emerging immunotherapies for leukemia and lymphoma, molecular markers predicting disease relapse, and innovative treatment regimens such as all-oral therapies for acute myeloid leukemia.

Solid tumor studies focus on disparities in gastric cancer, machine learning applications for breast cancer metastasis, and promising antibody-drug conjugates for lung cancer. Investigations related to melanoma and skin cancer examine circulating tumor DNA as a marker for disease progression, comparative survival analyses based on biomarkers, and the identification of targetable mutations across different skin cancer types. These findings underscore the breadth of ongoing efforts at John Theurer Cancer Center—New Jersey’s largest cancer center—to refine therapeutic strategies, enhance precision oncology, and improve patient outcomes.

Multiple Myeloma Research

Carfilzomib, iberdomide, and dexamethasone in patients with transplant-eligible newly diagnosed multiple myeloma: Updated results from phase 1/2 study

Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy

Real-world outcomes of patients with multiple myeloma treated with T-cell engagers compared to those treated on clinical trials

Impact of racial disparities on efficacy and safety outcomes for patients with relapsing/refractory multiple myeloma receiving T-cell engagers

Heterogeneity in the expression of GPRC5D between patients with multiple myeloma

Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma

Global burden of multiple myeloma: Analysis from 1980 to 2021

Efficacy and safety of less frequent dosing with elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3
Leukemia and Lymphoma

Peripheral blood cell-free DNA testing as a predictor for relapse post-allogeneic stem cell transplant for acute myeloid leukemia

An all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts

Employing novel pan-cancer targets for immunotherapy in leukemias and solid tumors

MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis

Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)

Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients with relapsed/refractory large B-cell lymphoma and complete response at 2 years with epcoritamab monotherapy

TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager, in patients with relapsed or refractory B-cell malignancies
Solid Tumor Research

Limited changes in the central nervous system immune microenvironment in patients with breast cancer metastasis and capturing these changes using machine learning

Relationship between FOLR1 expression and pan-cancer subgroup of tumors with specific transcriptomic profile

Disparities and trends in gastric cancer: Incidence, mortality, and stage-specific trends

Prevalence of the HPV, EBV, and TTV viral RNA in the plasma of patients with solid and hematologic neoplasms and the detection of a specific immune signature

Global trends in soft tissue and extraosseous sarcomas (1980–2021): Regional and economic disparities

ZL-1310, a DLL3 antibody-drug conjugate, in patients with extensive stage small cell lung cancer: Phase 1 trial update

Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma

Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis

Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors

A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors

A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors

A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer
Melanoma and Other Skin Cancers

Comparison of ctDNA and hematologic ratios as markers of disease progression in early versus late-stage melanoma: A single-center retrospective study

Survival analysis based on markers of progression in melanoma: A single-center comparison of survival in patients with high vs low biomarkers

Targetable mutations in cutaneous skin cancers: A comparative study across melanoma, squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma

On May 29, 2025 Accuray Incorporated (NASDAQ: ARAY) reported its participation in the Jefferies Global Healthcare Conference 2025 (Press release, Accuray, MAY 29, 2025, View Source [SID1234653492]). The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days.

On May 29, 2025 Accuray Incorporated (NASDAQ: ARAY) reported its participation in the Jefferies Global Healthcare Conference 2025 (Press release, Accuray, MAY 29, 2025, View Source [SID1234653492]). The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days.